David M. Nanus

Also affiliated with Cornell University, New York Hospital Queens, Lander Institute, Presbyterian Hospital, Weill Cornell Medicine

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

File S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

(2023)10.1158/1541-7786.22527275

Top 100%

0DataRank

Top 100%0 citations

Susan Halabi, Gábor Kemény, Monika Anand, Paraskevi Giannakakou, David M. Nanus +4 more

Papers

Driven by 42 papers — median percentile 0. Top paper: “Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591”.

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

Journal of Clinical Oncology(2023)10.1200/jco.23.00573

N/A

2.6DataRank · unranked

69 citations

Charlene Thomas, Oliver Sartor, Michael Sun, Judith Stangl‐Kremser, Mahelia Bissassar +10 more

Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer

The Prostate(2021)10.1002/pros.24104

N/A

1.5DataRank · unranked

27 citations

Muhammad Junaid Niaz, Myrto Skafida, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer

The Oncologist(2020)10.1634/theoncologist.2020-0028

N/A

0.550DataRank · unranked

38 citations

Jaspreet S. Batra, Ryan D. Walsh, Marigdalia K. Ramirez‐Fort, Shankar Vallabhajosula, Yuliya Jhanwar +6 more

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3471

N/A

0.546DataRank · unranked

37 citations

Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus +19 more

Highly portable quantitative screening test for prostate-specific antigen at point of care

Current Research in Biotechnology(2021)10.1016/j.crbiot.2021.11.003

N/A

0.505DataRank · unranked

28 citations

David M. Nanus, David Erickson, Saurabh Mehta, Balaji Srinivasan

The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3017

N/A

0.406DataRank · unranked

14 citations

Siyuan Guo, Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis +8 more

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5018

N/A

0.360DataRank · unranked

10 citations

Michael Philip Sun, Jones T. Nauseef, Charlene Thomas, Sandra Huicochea Castellanos, Joseph Earl Thomas +12 more

Novel genetically engineered mouse models for clear cell renal cell carcinoma

Scientific Reports(2023)10.1038/s41598-023-35106-7

N/A

0.324DataRank · unranked

4 citations

Kristian B. Laursen, Leiping Fu, Francesca Khani, Lukas E. Dow, Dawid G. Nowak +5 more

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution

European Urology Oncology(2025)10.1016/j.euo.2025.05.014

N/A

0.269DataRank · unranked

5 citations

Marshall A. Diven, Brady Rippon, Christopher E. Barbieri, Jim C. Hu, Douglas S. Scherr +20 more

Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5100

N/A

0.269DataRank · unranked

5 citations

Joseph R. Osborne, Peter Gregos, Charlene Thomas, Mahelia Bissassar, Sharon Singh +14 more

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.158

N/A

0.176DataRank · unranked

1 citations

Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez +10 more

The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.05.07.538753

N/A

0.165DataRank · unranked

2 citations

William F. Hooper, Timothy R. Chu, Heather Geiger, Jennifer Shelton, Minita Shah +21 more

Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.183

N/A

0.165DataRank · unranked

2 citations

Susan Halabi, Joseph D. Schonhoft, Jun Luo, David M. Nanus, Paraskevi Giannakakou +13 more

PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.5070

N/A

0.104DataRank · unranked

1 citations

Charlene Thomas, Gabriel Raab, Aaron N. Holmes, Tobechukwu Okobi, Andres Ricaurte‐Fajardo +11 more

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.120

N/A

0.104DataRank · unranked

1 citations

Michael Sun, Jones T. Nauseef, Muhammad Junaid Niaz, Dunya Imad, Paul J. Christos +11 more

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps216

N/A

0DataRank · unranked

9 citations

Joseph R. Osborne, Matthew C. Dallos, Jones T. Nauseef, Cora N. Sternberg, Peter Gregos +11 more

Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.037

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Michael Sun, Oliver Sartor, Sharon Singh, Mahelia Bissassar +15 more

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.077

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Benedict Ho, Juana Martinez Zuloaga, Brian D. Gonzalez, Michael Sun +15 more

Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Urologic Oncology Seminars and Original Investigations(2020)10.1016/j.urolonc.2020.05.028

N/A

0DataRank · unranked

49 citations

Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas, Paul J. Christos +8 more

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3233

N/A

0DataRank · unranked

25 citations

Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore +8 more

NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma

Cancer Biology & Therapy(2023)10.1080/15384047.2023.2170669

N/A

0DataRank · unranked

19 citations

Kristian B. Laursen, Ryan Schreiner, Ryan M. Williams, Johannes C. van der Mijn, Michael J. Crowley +5 more

Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program

Cancer Causes & Control(2023)10.1007/s10552-023-01807-7

N/A

0DataRank · unranked

8 citations

Hari S. Iyer, Rulla M. Tamimi, David M. Nanus, Timothy R. Rebbeck, Kevin H. Kensler +1 more

Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

(2023)10.1158/1078-0432.c.6530474.v1

N/A

0DataRank · unranked

0 citations

Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus +19 more

File S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

(2023)10.1158/1541-7786.22527275

Top 100%

0DataRank

Top 100%0 citations

Susan Halabi, Gábor Kemény, Monika Anand, Paraskevi Giannakakou, David M. Nanus +4 more

Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.5074

N/A

0DataRank · unranked

5 citations

Charlene Thomas, Jones T. Nauseef, Oliver Sartor, Michael Philip Sun, Sandra Huicochea Castellanos +14 more

Deletion of the transcription factor ATF4 in a model of clear cell renal cell carcinoma

Neoplasia(2025)10.1016/j.neo.2025.101188

N/A

0DataRank · unranked

2 citations

Shireen Chikara, Eduardo Mere Del Aguila, Tuo Zhang, Jacob B. Geri, David M. Nanus +2 more

Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer

medRxiv(2025)10.1101/2025.07.01.25330467

N/A

0DataRank · unranked

0 citations

Alexander Martinez‐Fundichely, Sandra Cohen, Metin Balaban, Chen Khuan Wong, Weiling Li +26 more

Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17007

N/A

0DataRank · unranked

1 citations

Juana Martinez Zuloaga, Kritika Subramanian, Peter Gregos, Mahelia Bissassar, Sharon Singh +13 more

Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells

Oncogenesis(2020)10.1038/s41389-020-0222-3

N/A

0DataRank · unranked

22 citations

Zongxiang Zhou, Meredith L. Stone, Bao Lu, Andrea Flesken‐Nikitin, David M. Nanus +2 more

Differences in ambulatory care fragmentation between cancer survivors and noncancer controls

Cancer(2020)10.1002/cncr.32869

N/A

0DataRank · unranked

14 citations

Evgeniya Reshetnyak, Monika M. Safford, David M. Nanus, Lisa M. Kern, Laura C. Pinheiro

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.114

N/A

0DataRank · unranked

24 citations

Joseph R. Osborne, Muhammad Junaid Niaz, Shankar Vallabhajosula, Panagiotis J. Vlachostergios, Charlene Thomas +9 more

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5560

N/A

0DataRank · unranked

10 citations

Joseph R. Osborne, Escarleth Fernandez, Charlene Thomas, Muhammad Junaid Niaz, Amy Ciriaco +10 more

Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.8

N/A

0DataRank · unranked

2 citations

Alessandro Romanel, Vincenza Conteduca, Nicola Casiraghi, Michael Sigouros, Gian Marco Franceschini +13 more

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.45

N/A

0DataRank · unranked

2 citations

Sukanya Goswami, Muhammad Junaid Niaz, Charlene Thomas, Paul J. Christos, Joseph R. Osborne +10 more

AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.184

N/A

0DataRank · unranked

1 citations

Jun Luo, Monika Anand, Emmanuel S. Antonarakis, David M. Nanus, Paraskevi Giannakakou +10 more

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

UNC Libraries(2020)10.17615/41rk-2070

N/A

0DataRank · unranked

0 citations

Matthew D. Galsky, Iain J. Webb, Jesika Petruck, Michael J. Morris, Robert Dreicer +7 more

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

Frontiers in Oncology(2021)10.3389/fonc.2021.630589

N/A

0DataRank · unranked

43 citations

Muhammad Junaid Niaz, Michael Sun, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5015

N/A

0DataRank · unranked

30 citations

Michael Sun, Oliver Sartor, Charlene Thomas, Sharon Singh, Mahelia Bissassar +11 more

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in Castrate-Resistant Prostate Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.06.03.446940

N/A

0DataRank · unranked

2 citations

Mohd Azrin Bin Jamalruddin, CheukMan C. Au, Eiman Mukhtar, Luigi Portella, Adeline Berger +5 more

Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer

medRxiv(2021)10.1101/2021.11.01.21265757

N/A

0DataRank · unranked

2 citations

Bob Zimmermann, Giuseppe Galletti, Susan Halabi, Ada Gjyrezi, Qian Yang +16 more

Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5055

N/A

0DataRank · unranked

0 citations

Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg +4 more

Nearly All Cancer Survivors Return to Primary Care

The Journal of the American Board of Family Medicine(2022)10.3122/jabfm.2022.04.220007

N/A

0DataRank · unranked

17 citations

Mangala Rajan, Monika M. Safford, David M. Nanus, Lisa M. Kern, Laura C. Pinheiro

David M. Nanus

Indexed papers

Top data-sharing exemplar

Papers